Forsyth Douglas's Form 4 filing
Inhibrx Biosciences, Inc.INBX · filed Sep 8, 2026
- Accession no.
- 0001240801-26-000004
- Filed
- Sep 8, 2026, 4:26 PM ET
- Trade date
- Sep 8, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $286.6K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Forsyth DouglasCIK 0001240801 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Common Stock | PPurchaseAcquired | +2,500 | $114.65F1 | +$286,617.25 | 227,064 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares were purchased in multiple transactions at prices ranging from $114.36 to $114.689 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Referenced by the price of 1 transaction in Table I.